Talk:Glembatumumab vedotin

Dec 2012 poster of EMERGE final results
The EMERGE study shows the results presented in Dec 2012. Its conclusions are : "EMERGE results consistent with previous study in similar population * CDX-011 well-tolerated ‒ Less hematologic toxicity but more rash and neuropathy than Investigator’s Choice (IC) * Promising activity in triple-negative breast cancer (TNBC), where treatment options are limited  ‒ CDX-011 response rate of 19% in TNBC compared to 0% for IC * Significant tumor expression of GPNMB associated with greater activity  ‒ CDX-011 response rate of 32% compared to 13% for IC  ‒ Stromal expression of GPNMB did not appear to correlate with outcome.  ‒ High GPNMB expression in 41% of patients with TNBC  ‒ CDX-011 response rate of 33% and doubling of PFS (p=0.008) and OS (p=0.003) * A registrational study is being planned." Could mention PFS etc in main article. - Rod57 (talk) 00:46, 4 February 2013 (UTC)